68 related articles for article (PubMed ID: 17412448)
1. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
Mathew A; Peiffer LP; Rhoades K; McGarrity TJ
Health Qual Life Outcomes; 2006 May; 4():30. PubMed ID: 16696859
[TBL] [Abstract][Full Text] [Related]
2. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
Ahlenstiel G; Edlich B; Hogdal LJ; Rotman Y; Noureddin M; Feld JJ; Holz LE; Titerence RH; Liang TJ; Rehermann B
Gastroenterology; 2011 Oct; 141(4):1231-9, 1239.e1-2. PubMed ID: 21741920
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Marks KM; Kitch D; Chung RT; Hadigan C; Andersen J; Tien P; Luetkemeyer A; Alston-Smith B; Glesby MJ;
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):345-9. PubMed ID: 24525470
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ribavirin in patients with hepatitis C virus.
Wade JR; Snoeck E; Duff F; Lamb M; Jorga K
Br J Clin Pharmacol; 2006 Dec; 62(6):710-4. PubMed ID: 17118126
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Gutierrez-Valencia A; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Espinosa N; Castillo-Ferrando JR; Viciana P; Lopez-Cortes LF
Antimicrob Agents Chemother; 2015; 59(6):3257-62. PubMed ID: 25801562
[TBL] [Abstract][Full Text] [Related]
6. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
Naik GS; Tyagi MG
J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
[TBL] [Abstract][Full Text] [Related]
7. Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.
Sehgal M; Zeremski M; Talal AH; Khan ZK; Capocasale R; Philip R; Jain P
J Clin Cell Immunol; 2014 Oct; 5():. PubMed ID: 25705565
[TBL] [Abstract][Full Text] [Related]
8. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
Hatu G; Bailly F; Pourcelot E; Pradat P; Miailhes P; Maynard M; Parant F; Chiarello P; Livrozet JM; Zoulim F; Gagnieu MC
BMC Infect Dis; 2014 Mar; 14():150. PubMed ID: 24650094
[TBL] [Abstract][Full Text] [Related]
9. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
Rotman Y; Noureddin M; Feld JJ; Guedj J; Witthaus M; Han H; Park YJ; Park SH; Heller T; Ghany MG; Doo E; Koh C; Abdalla A; Gara N; Sarkar S; Thomas E; Ahlenstiel G; Edlich B; Titerence R; Hogdal L; Rehermann B; Dahari H; Perelson AS; Hoofnagle JH; Liang TJ
Gut; 2014 Jan; 63(1):161-9. PubMed ID: 23396509
[TBL] [Abstract][Full Text] [Related]
10. Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.
Dahari H; Cotler SJ; Layden TJ; Perelson AS
J Hepatol; 2013 Apr; 58(4):840-2. PubMed ID: 23246507
[No Abstract] [Full Text] [Related]
11. Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
Chung WJ
Clin Mol Hepatol; 2012 Sep; 18(3):268-71. PubMed ID: 23091806
[No Abstract] [Full Text] [Related]
12. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.
Araújo ES; Dahari H; Neumann AU; de Paula Cavalheiro N; Melo CE; de Melo ES; Layden TJ; Cotler SJ; Barone AA
J Viral Hepat; 2011 Apr; 18(4):e52-60. PubMed ID: 20738775
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU
J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Viral Kinetics in Special Populations.
Dahari H; Layden-Almer JE; Perelson AS; Layden TJ
Curr Hepat Rep; 2008; 7(3):97-105. PubMed ID: 19148305
[TBL] [Abstract][Full Text] [Related]
15. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
Dahari H; Markatou M; Zeremski M; Haller I; Ribeiro RM; Licholai T; Perelson AS; Talal AH
J Hepatol; 2007 Jul; 47(1):23-30. PubMed ID: 17412448
[TBL] [Abstract][Full Text] [Related]
16. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
18. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
Sauleda S; Juárez A; Esteban JI; Altisent C; Ruiz I; Puig L; Esteban R; Guardia J
Hepatology; 2001 Nov; 34(5):1035-40. PubMed ID: 11679976
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
